United Therapeutics price target raised to $500 from $400 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on United Therapeutics (UTHR) to $500 from $400 and keeps a Buy rating on the shares. The firm believes the positive TETON-2 data positions Tyvaso as one of the few late-stage Idiopathic pulmonary fibrosis therapies to deliver consistent benefit across lung function, quality of life, and multiple patient subgroups.